Bristol Myers Squibb (BMY) Q2 2026 Earnings
How Did BMY Stock React to Q2 2026 Earnings?
S&P 500 over the same 30 days: +3.42%.
Did BMY Beat Earnings? Q2 2026 Results
Yes. Bristol Myers Squibb reported Q2 2026 earnings of $2.04 a share on Jul 30, 2026, beating the $1.60 consensus estimate by 27.7%. Revenue was $13.0B against a $11.7B estimate.
Bristol Myers Squibb delivered a standout second quarter for fiscal 2026, posting adjusted diluted EPS of $2.04 and revenue of $12.97 billion, beating the Street's respective estimates of $1.60 and $11.74 billion by 27.74% and 10.53%, marking the company's fifth consecutive quarter of consensus EPS beats. The top-line result represented 5.7% growth year-over-year, powered largely by the Growth Portfolio, which hit $7.56 billion on the strength of Opdivo Qvantig, Camzyos, Breyanzi, and Reblozyl, while Eliquis surged 22% to $4.48 billion on sustained U.S. demand and market share gains. The quarter's momentum also reflects the absence of the $1.51 billion in Acquired IPRD charges that weighed on year-ago results, allowing earnings to expand sharply. The strong performance prompted management to raise full-year non-GAAP revenue guidance to roughly $49.00 billion to $50.00 billion from the prior $46.00 billion to $47.50 billion, and lift EPS guidance to $6.75 to $7.00, with Eliquis growth expectations now set at 20% to 25% for the year.
- Growth Portfolio revenue increased 15% YoY to $7.6 billion, driven by Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi, and Opdualag
- Eliquis revenue grew 22% to $4.5 billion on continued U.S. demand growth and market share gains
- Camzyos revenue grew 60% driven by strong global demand and market penetration in oHCM
- Breyanzi grew 41% as leading CD19 directed CAR T across B-cell malignancies with growing community outpatient adoption
- Legacy Portfolio declined 4% due to generic erosion in Revlimid, Pomalyst/Imnovid, and other mature brands
- Non-GAAP gross margin declined 120 bps to 71.4% reflecting change in product mix
“The Growth Portfolio continues to deliver, achieving 15% growth in the quarter, and represents an expanding share of our overall business.”
Bristol Myers Squibb CEO, on the earnings call
What Is Bristol Myers Squibb's Outlook?
Bristol-Myers Squibb raised its 2026 full-year non-GAAP revenue guidance to approximately $49.0 billion to $50.0 billion, up from the prior range of approximately $46.0 billion to $47.5 billion, reflecting broad-based portfolio momentum. Non-GAAP EPS guidance increased to $6.75–$7.00 from $6.05–$6.35. Full-year operating expenses are now expected to be approximately $16.5 billion (up from ~$16.3 billion), reflecting increased investment behind key pipeline programs and new product launches. Gross margin guidance of ~69%–70%, effective tax rate of ~18%, and other income/expense of ~($700 million) were unchanged. Worldwide Eliquis revenue growth guidance was raised to 20%–25% from the prior 10%–15%. The company expects the Legacy Portfolio to decline 4%–6% for the year.
BMY YoY Financials
| Metric | Q2 2026 | Q2 2025 | Year over year |
|---|---|---|---|
| Revenue | $13.0B | $12.3B | +5.7% |
| Gross Profit | $9.2B | $8.1B | +14.6% |
| Operating Income | $4.1B | $4.1B | −0.7% |
| Net Income | $3.3B | $1.3B | +153.2% |
BMY Revenue by Segment
BMY Revenue by Geography
When Does Bristol Myers Squibb Report Next?
Figures from SEC filings and company reports. Not investment advice.